An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
Colorectal Cancer|Colorectal Tumors|Colorectal Carcinoma|Colorectal Neoplasm
BIOLOGICAL: Nivolumab|DRUG: Trametinib|BIOLOGICAL: Ipilimumab|DRUG: Regorafenib
Incidence of dose limiting toxicity (DLTs), Up to 23 months|Incidence of Adverse Events (AEs), Approximately 100 months|Incidence of Serious Adverse Events (SAEs), Approximately 100 months|Incidence of Deaths, Up to 100 months|Incidence of clinically significant changes in clinical laboratory results: Hematology tests, Up to 77 months|Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests, Up to 77 months|Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests, Up to 77 months|Objective response rate (ORR) by investigator (Part 1B and Part 2), Approximately 24 months
Objective response rate (ORR) (Part 1A and Part 1), Approximately 24 months|Disease control rate (DCR), Approximately 24 months|Duration of response (DOR), Approximately 24 months|Time to response (TTR), Approximately 24 months|Progression-free survival (PFS) by investigator per response evaluation criteria in solid tumors (RECIST) v1.1, Approximately 24 months|Best overall response (BOR), Up to 24 months|Overall survival (OS), Approximately 40 months|Incidence of Adverse Events (AEs), Approximately 100 months|Incidence of Serious Adverse Events (SAEs), Approximately 100 months|Incidence of Deaths, Up to 100 months|Incidence of clinically significant changes in clinical laboratory results: Hematology tests, Up to 77 months|Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests, Up to 77 months|Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests, Up to 77 months
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.